Celgene Corp. earlier this week announced that the Food and Drug Administration approved Otezla (apremilast) for the treatment of moderate to severe plaque psoriasis. The drug is the first and only PDE4 inhibitor approved for the treatment of plaque psoriasis, according to the company.
Diplomat on Monday announced that it is one of a select group of specialty pharmacies contracted by Celgene to distribute Otezla (apremilast), a new medication for the treatment of psoriatic arthritis.
Just days after the Food and Drug Administration approved Otezla, a new oral therapy to treat active psoriatic arthritis in adult patients, Avella Specialty Pharmacy on Friday announced that it is prepared to begin distributing the drug.
Celgene on Friday announced that the Food and Drug Administration has approved Otezla (apremilast), the company's oral, selective inhibitor of phosphodiesterase 4 (PDE4), for the treatment of adult patients with active psoriatic arthritis.
Arthritis is one of the most common chronic illnesses in children, but it often goes unnoticed and undiagnosed, according to two arthritis-focused organizations seeking to spread awareness about the disease.